drugset / Trial / NCT06957821

Study to Image Inflammatory Activity of a Fluorescence Imaging Agent in Excised Human Artery Plaques

NCT06957821 ↗

RandomizedParallel-groupSingle-blindOther

Summary

Active inflammation plays a key role in causing Coronary Artery Disease (CAD) and Peripheral Arterial Disease (PAD). Since inflammation is so important in how these diseases start, are diagnosed, and treated, being able to see it clearly in each patient could lead to more personalized and effective care - and may help prevent heart attacks. Right now, there's no imaging technology available to clearly see inflammation inside the coronary arteries. The investigators hope to learn how an imaging drug; called LUMISIGHT (Pegulicianine) can help detect inflammation in blood vessels compared with saline. If the investigators find out that LUMISIGHT is active in humans, the investigators might be able to use it for detecting plaque risk in the future.

Timeline

Start
2026-06
Primary completion
2028-07
Completion
2029-12

Drugs

EvaluationDrugModalityDoseRoute
Subject PEGULICIANINE ACETATE Diagnostic / imaging agent 1 mg/kg —